HomeTrialNCT07214727
🔬NCT07214727Phase 1RECRUITING

A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease

Study Summary

The purpose of this study is to: * Evaluate the safety and tolerability of intrathecal (IT) ALN-5288 in patients with Alzheimer's Disease (AD) * Evaluate the pharmacodynamic (PD) and pharmacokinetic (PK) effects of ALN-5288 after dose administration

Interventions / Drugs
View on ClinicalTrials.gov ↗
Study Details
Enrollment50 participants
Primary Completion
Lead SponsorAlnylam Pharmaceuticals
Data Retrieved2026-04-11 02:53:26.219297+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.